[go: up one dir, main page]

MXPA06000401A - Derivados de naftileno como inhibidores de citocromo p450. - Google Patents

Derivados de naftileno como inhibidores de citocromo p450.

Info

Publication number
MXPA06000401A
MXPA06000401A MXPA06000401A MXPA06000401A MXPA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A MX PA06000401 A MXPA06000401 A MX PA06000401A
Authority
MX
Mexico
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
MXPA06000401A
Other languages
English (en)
Inventor
Patricia Anne Beck
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MXPA06000401A publication Critical patent/MXPA06000401A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Los compuestos de la formula (ver formula (I)) y sales farmaceuticamente aceptables de los mismos, en donde n1, n2, n3, n4, G1, Q1, Z, R1, R2, R3, R4a, R5a, y R5b son definidos arriba, inhiben la enzima de citocromo P450RAI y son utiles para el tratamiento y/o prevencion de varias enfermedades y condiciones que responden a tratamiento por retinoides y por acido retinoico que se presenta naturalmente.
MXPA06000401A 2003-07-10 2004-07-12 Derivados de naftileno como inhibidores de citocromo p450. MXPA06000401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
PCT/US2004/022282 WO2005007631A1 (en) 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors

Publications (1)

Publication Number Publication Date
MXPA06000401A true MXPA06000401A (es) 2006-03-17

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000401A MXPA06000401A (es) 2003-07-10 2004-07-12 Derivados de naftileno como inhibidores de citocromo p450.

Country Status (15)

Country Link
EP (1) EP1654236A1 (es)
JP (1) JP4832295B2 (es)
KR (1) KR20060052799A (es)
CN (1) CN1819996B (es)
AU (1) AU2004257257B2 (es)
BR (1) BRPI0412424A (es)
CA (1) CA2532078A1 (es)
IL (1) IL172812A0 (es)
IS (1) IS8223A (es)
MX (1) MXPA06000401A (es)
NO (1) NO20060114L (es)
RU (1) RU2363696C2 (es)
SG (1) SG144941A1 (es)
UA (1) UA87822C2 (es)
WO (1) WO2005007631A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696899A1 (en) 2003-12-17 2006-09-06 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
AU2011261586B2 (en) 2010-06-01 2015-08-27 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
CA2817691C (en) * 2010-11-13 2020-09-01 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103328452A (zh) * 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CN112961149A (zh) 2014-08-11 2021-06-15 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
EP3240778A4 (en) 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
CN116903531B (zh) * 2023-07-21 2025-12-12 上海中医药大学 细胞色素p450酶3a4的抑制剂及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (es) * 1960-05-04
NL131915C (es) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
ID24175A (id) * 1997-11-28 2000-07-13 Lg Chemical Ltd Turunan-turunan imidazol yang mempunyai aktivitas penghambatan untuk farnesil transferase dan proses pembuatannya
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
US6573289B1 (en) * 1998-04-23 2003-06-03 Takeda Chemical Industries, Ltd. Naphthalene derivatives, their production and use
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion

Also Published As

Publication number Publication date
IS8223A (is) 2006-01-10
IL172812A0 (en) 2006-06-11
WO2005007631A1 (en) 2005-01-27
RU2006103996A (ru) 2006-07-10
CN1819996B (zh) 2010-10-27
CA2532078A1 (en) 2005-01-27
RU2363696C2 (ru) 2009-08-10
JP2007523866A (ja) 2007-08-23
BRPI0412424A (pt) 2006-09-05
UA87822C2 (ru) 2009-08-25
AU2004257257B2 (en) 2011-05-12
AU2004257257A1 (en) 2005-01-27
KR20060052799A (ko) 2006-05-19
CN1819996A (zh) 2006-08-16
EP1654236A1 (en) 2006-05-10
JP4832295B2 (ja) 2011-12-07
NO20060114L (no) 2006-02-09
SG144941A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
MXPA06000401A (es) Derivados de naftileno como inhibidores de citocromo p450.
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
MX2009007050A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
MXPA04010055A (es) Derivados de tioxantina como inhibidores de mieloperoxidasa.
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
BR0316583A (pt) Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
MY145306A (en) Thieno [3,2-d] pyrimidine derivative useful as p13k inhibitor
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
SE0301232D0 (sv) Novel use
GB0406279D0 (en) Therapeutic compounds
MY140841A (en) Indozolone derivatives as 11b-hsd1 inhibitors
GB0406282D0 (en) Therapeutic compounds
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
SI1601646T1 (sl) 2-substitirani vitamin d analogi in njihova terapevtska uporaba
EP1775283A4 (en) 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1)
MX2007013624A (es) Inhibidores de proteina cinasa.
TNSN06338A1 (en) Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor
SE0302756D0 (sv) Novel Compounds
TW200407133A (en) Novel PPARα and PPARγ agonists
AU2003242592A1 (en) Amide derivatives as inhibitors of the enzymatic activity of renin
MX2025000498A (es) Formas sólidas de un derivado de triazina como modulador del gen oncogénico de linfoma b de casitas (cbl-b).
TNSN08531A1 (en) Phenylacetic acid derivatives as cox - 2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration